Zobrazeno 1 - 10
of 424
pro vyhledávání: ''
Autor:
Ericka Sohlberg, Manisha Desai, Chirag J. Patel, Mary K. Goldstein, Glenn M. Chertow, Jaden Yang, Todd H. Wagner, I-Chun Thomas, Kyla N. Velaer, James D. Brooks, Kristopher Kapphahn, John T. Leppert
Publikováno v:
Cancer
Background Estimates of overall patient health are essential to inform treatment decisions for patients diagnosed with cancer. The authors applied XWAS methods, herein referred to as "laboratory-wide association study (LWAS)", to evaluate association
Autor:
Robert E. Godin, Jin Seok Ahn, Joon Ho Shim, Myung-Ju Ahn, Keunchil Park, Hyun Ae Jung, Peter S. Mortimer, Jong-Mu Sun, Sehhoon Park, Woong-Yang Park, Simon Smith, Se-Hoon Lee, Simon J. Hollingsworth, Heejung (Rosa) Kim
Publikováno v:
Cancer. 126:4002-4012
Background A high percentage of small cell lung cancer (SCLC) cases harbor cell cycle-related gene mutations and RICTOR amplification. Based on underlying somatic mutations, the authors have conducted a phase 2 biomarker-driven, multiarm umbrella stu
Autor:
Itay Ricon-Becker, Steve W. Cole, Oded Zmora, Mordechai Gutman, Shamgar Ben-Eliyahu, R. Haldar, Arielle Radin
Publikováno v:
Cancer. 126:3991-4001
BACKGROUND Preclinical studies have implicated excess release of catecholamines and prostaglandins in the mediation of prometastatic processes during surgical treatment of cancer. In this study, we tested the combined perioperative blockade of these
Autor:
Bhakti Dwivedi, Adam I. Marcus, Suresh S. Ramalingam, Manali Rupji, Brian Pedro, Paula M. Vertino, Jeanne Kowalski, Jessica Konen, Taofeek K. Owonikoko
Publikováno v:
Cancer
Background Intratumoral heterogeneity is defined by subpopulations with varying genotypes and phenotypes. Specialized, highly invasive leader cells and less invasive follower cells are phenotypically distinct subpopulations that cooperate during coll
Autor:
Susanne K. Pedersen, Frederick S. Jones, Christos S. Karapetis, David M. Murray, Susan E Byrne, Paul Hollington, Eva Segelov, Graeme P. Young, Philippa Rabbitt, Amitesh Roy, Lawrence C. LaPointe, Erin L. Symonds
Publikováno v:
Cancer
Background The sensitive detection of recurrent colorectal cancer (CRC) by the measurement of circulating tumor DNA (ctDNA) might improve the chance of a cure. This study compared a quantitative methylated ctDNA test with carcinoembryonic antigen (CE
Autor:
Shenqi Zhang, Marcus Bosenberg, Lucia B. Jilaveanu, Jiangbing Zhou, Adebowale J. Adeniran, Victor O. Oria, Harriet M. Kluger, Chetan K. Rane, Gang Deng, Thuy Tran, Christopher R. Zito, Sarah A. Weiss, Fanfan Zhang, Yuval Kluger, Huifang Zhu, Hongyi Zhang
Publikováno v:
Cancer
Background PLEKHA5 has previously been identified as a novel molecule implicated in melanoma brain metastasis, a disease that continues to portend a poor prognosis. The aim of this study was to further investigate the functional role of PLEKHA5 in di
Autor:
Wei Lei Yang, Usha Menon, Bryan Fellman, Joseph Celestino, Steven J. Skates, Robert C. Bast, Zhen Lu, Samir M. Hanash, Jing Guo, Jing Ning, Makoto Kobayashi, Karen H. Lu
Publikováno v:
Cancer
BACKGROUND Early detection of ovarian cancer could significantly improve patient outcomes. Cancer antigen 125 (CA 125) is elevated in sera from approximately 60% of patients with early-stage (I/II) disease. Sensitivity might be improved through the c
Autor:
Elisa Ledet, Mehmet Asim Bilen, Guru Sonpavde, Petros Grivas, Jue Wang, Rebecca J. Nagy, Michael B. Lilly, Gurudatta Naik, Shilpa Gupta, Amir Ali Talasaz, Lakshminarayanan Nandagopal, Oliver Sartor, Roberto Nussenzveig, Andrew W. Hahn, Gregory R. Pond, Sumanta K. Pal, Richard B. Lanman, Neeraj Agarwal, Theodore Stewart Gourdin, Andrew J. Armstrong
Publikováno v:
Cancer. 125:1459-1469
Background Because cell-free DNA (cfDNA) analysis facilitates the noninvasive genomic profiling of metastatic castration-resistant prostate cancer (mCRPC), the authors evaluated the association between cfDNA alterations and outcomes and evolution wit
Autor:
Peter H. O'Donnell, Richard Martin Bambury, Richard C. Chao, Joaquim Bellmunt, Elizabeth A. Guancial, Guru Sonpavde, Noah M. Hahn, Joel Picus, Amir Mortazavi, James G. Christensen, Diane Potvin, Demiana Faltaos, Ajjai Alva, Jonathan E. Rosenberg, Petros Grivas, Sumanta K. Pal, Sumati Gupta, Matthew I. Milowsky, Lowell L. Hart
Publikováno v:
Cancer
Background The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] hi
Autor:
Paul J. Goodfellow, Floor J. Backes, Jennifer Haag, Adrian A. Suarez, Casey M. Cosgrove, David E. Cohn
Publikováno v:
Cancer. 125:398-405
Background The objective of this study was to assess the correlation between mismatch repair (MMR) status, disease recurrence patterns, and recurrence-free survival (RFS) in patients with high-intermediate-risk (HIR) endometrioid endometrial cancer (